[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diagnoses-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diagnoses-disease":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,79,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100549887","optimizing-bronchopulmonary-cancer-screening-100549887",false,"NCT06439901","Optimizing Bronchopulmonary Cancer Screening","Optimizing the Implementation of Bronchopulmonary Cancer Screening in the Ile de France Region (OPTI-DEPIST-MUT)","OPTI-DEPIST","Inclusion Criteria:\n\n* Participant aged 50 to 74.\n* Resident in the Île-de-France region.\n* Active smoker or quit smoker for 10 years or less:\n\n  1. more than 10 cigarettes a day for more than 30 years,\n  2. more than 15 cigarettes a day for more than 25 years.\n* The participant has been informed and has signed the consent form.\n* Social Security System affiliation.\n* Willingness to participate in a smoking cessation program, if currently smoking.\n\nExclusion Criteria:\n\n* Active cancer or a history of cancer in remission for less than 5 years (except basal cell carcinoma of th skin or epithelioma in situ of the uterine cervix).\n* Presence of symptoms suggestive of bronchopulmonary cancer. Participants with these symptoms require immediate diagnostic investigations and are therefore not eligible for screening.\n* Weight \\>= 140 kg.\n* Severe comorbidity contraindicating therapeutic options or invasive thoracic diagnostic investigations.\n* Inability to climb two flights of stairs without stopping.\n* A thoracic CTscan performed within the previous year.\n* Persons deprived of liberty or under guardianship.\n* Impossibility to undergo the medical monitoring of the trial for geographical, social or psychological reasons.","ALL","50 Years","74 Years",{"count":21,"type":22},500,"ESTIMATED","INTERVENTIONAL",[25],"NA","The aim of this study is to evaluate the feasibility of performing a first screening for bronchopulmonary cancer by thoracic scanner in a French cohort within a dedicated, effective and structured network in the pilot centers participating in the study.",[28,29],"Bronchopulmonary Disease","Diagnoses Disease",[31,32,33],"bronchopulmonary cancer","screening","primary prevention","RECRUITING","2026-05-29",{"date":37,"type":38},"2026-06-02","ACTUAL",{"date":40,"type":38},"2025-01-27",{"date":42,"type":22},"2034-02-05",{"name":44,"class":45},"Institut Curie","OTHER",8,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100563464","artificial-intelligence-for-highly-myopic-cataract-100563464","NCT06616506","Artificial Intelligence for Highly Myopic Cataract","AI-HMC","Inclusion Criteria:\n\nAxial length ≥ 26 mm and patients with high myopia complicated by cataracts who visit our hospital.\n\nPreoperative anterior segment photography and cataract severity assessment, along with fundus OCT examination, have been performed.\n\nIf surgical treatment is conducted, the postoperative follow-up period should be no less than 1 month.\n\nThere are no missing clinical data before and after the surgery.\n\nExclusion Criteria:\n\nPatients who are unable to cooperate with the required examinations for this study.",{"count":55,"type":22},500000,"OBSERVATIONAL","This study aims to establish a multi-center artificial intelligence model for the accurate calculation of intraocular lens and its clinical application in highly myopic cataract, so as to improve the accuracy of the prediction of postoperative diopter in highly myopic cataract patients.",[59,60,61,62,63,29],"Cataract","High Myopia","Myopia","Automatic Judgement","Risk Reduction",[65,66,67,68],"highly myopic cataract","artificial intelligence","cataract","big data","2026-05-06",{"date":71,"type":38},"2026-05-11",{"date":73,"type":38},"2016-01-01",{"date":75,"type":22},"2035-12-31",{"name":77,"class":45},"Shanghai High Myopia Study Group",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100430895","early-detection-of-endometrialovarian-cancer-and-hereditary-predisposition-of-these-cancers-100430895","NCT04891029","Early Detection of Endometrial\u002FOvarian Cancer and Hereditary Predisposition of These Cancers","Phase III Diagnostic Trial for Early Detection of Endometrial\u002FOvarian Cancer and Hereditary Predisposition of These Cancers","Inclusion Criteria:\n\n\\- Capacity to understand study and provide informed consent\n\nExclusion Criteria:\n\n* Prior hysterectomy\n* Be pregnant\n* Be nursing\n* Be undergoing any fertility treatment\n* Have had recent history of uterine perforation",true,"FEMALE","45 Years","75 Years",{"count":91,"type":22},5600,[25],"Early stage high-grade cancer, endometrial and ovarian, has few, if any, symptoms or signs. When symptoms appear, the disease is commonly in advanced stage meaning it has left the gynaecological organs and metastasized to the pelvic\u002Fabdominal cavity. The McGill research group had showed in the DOvEE trial (NCT02296307), that fast-track assessment with transvaginal ultrasound scans (TVUS) and serial CA125 of women with vague symptoms associated with ovarian and endometrial cancer did diagnose these cancers earlier in the disease trajectory, with low-volume resectable disease, but only after the cancer had already become Stage III. One way to detect these cancers earlier is to screen asymptomatic women. Unfortunately, none of the currently available tests, including TVUS and CA-125 have been shown to be useful for screening for ovarian or endometrial cancer.\n\nThe McGill team has developed a genomic assay to screen and detect these cancers earlier in the trajectory than is currently the case. The test identifies pathogenic somatic mutations (necessary early steps in the development of these cancers), in an uterine cytological sample. It is able to do so by incorporating a machine-learning derived classifier that can discriminate the mutational signature of these cancers from benign disease with a sensitivity of 80% and a specificity of 100% in a healthy population of peri- and post-menopausal women. In addition to the uterine sample, the test includes a saliva sample that acts as an internal control but can also identify germline pathogenic variants that predispose to hereditary endometrial\u002Fovarian cancers as well as breast, pancreas, and colon cancers.\n\nThe test was developed in a retrospective population in whom the assay was done pre-operatively and the diagnosis of malignancy versus benign gynecological disease was confirmed by detailed pathological analysis of the uterus, tubes, and ovaries after surgical resection (NCT02288676). The test is now ready to be tested as a phase III diagnostic test in the general population to see if these results are just as promising in the community at large.",[29],[96,97,98,99,100],"Ovarian Cancer","Endometrial Cancer","Genomics","Screening","Early detection","2025-06-13",{"date":103,"type":38},"2025-06-17",{"date":105,"type":38},"2021-05-10",{"date":107,"type":22},"2028-11",{"name":109,"class":45},"McGill University",2,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":78},"100403661","establish-diagnostic-models-based-on-portal-venous-blood-for-pancreatic-cancer-100403661","NCT04536220","Establish Diagnostic Models Based on Portal Venous Blood for Pancreatic Cancer","Establish a Diagnostic Model Based on Multiple Molecule Profiling and Certain Established Markers for Identification of Pancreatic Cancer","Inclusion Criteria:\n\n1. age 18-75 years,male or female\n2. diagnosis or suspection of solid pancreatic mass based on previous imaging examination (ultrasonography, CT or MRI)\n3. lesion diameter larger than 1 cm\n4. signed informed consent letter\n\nExclusion Criteria:\n\n1. pregnant female\n2. Pancreatic cystic lesions\n3. Anticoagulant\u002Fantiplatelet therapy cannot be suspended\n4. unable or refuse to provide informed consent\n5. Coagulopathy (platelet count \\\u003C 50× 103\u002FμL,international normalized ratio \\> 1.5)\n6. Severe cardiopulmonary dysfunction that cannot tolerate intravenous anesthesia\n7. with history of mental disease\n8. other medical conditions that are not suitable for EUS-FNA","18 Years","80 Years",{"count":121,"type":22},300,"Explore new markers based on portal venous blood sampling to establish novel diagnostic models for identification of malignant pancreatic mass.",[29],[125],"diagnosis and pancreatic cancer","2024-03-28",{"date":128,"type":38},"2024-03-29",{"date":130,"type":38},"2024-01-01",{"date":132,"type":22},"2026-07-30",{"name":134,"class":45},"Changhai Hospital"]